Efficiency of anti‐VEGF therapy in central nervous system AML relapse: A case report and literature review. Issue 2 (3rd February 2022)

• Record Type: Journal Article
• Authors: Cao, Han‐Yu; Tao, Tao; Shen, Xiang‐Dong; Bai, Lian; Wan, Chao‐Ling; Wu, De‐Pei; Li, Jin‐Li; Xue, Sheng‐Li
• Is Part Of: Clinical case reports. Volume 10:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-03
• Subjects: AML -- anti‐VEGF therapy -- bevacizumab -- central nervous system (CNS); Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5367
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: There have been few reports on the treatment of central nervous system (CNS) acute myeloid leukemia (AML) relapse. This case study demonstrates that bevacizumab may be a viable treatment option when combined with IT chemotherapy as maintenance therapy for those with CNS leukemia. Abstract : Bevacizumab in combination with intrathecal chemotherapy is an effective therapy for acute leukemia patients with central nervous system involvement.